Daiichi Sankyo moves forward with innovative antimalarial drug research collaboration

This collaborative research project is funded through the GHIT Fund's Product Development Platform

mosquito-387707-640

Daiichi Sankyo Company, Limited , announced that it has entered into a new joint research agreement with Medicines for Malaria Venture (hereafter MMV) regarding Lead Optimization Project with the aim of developing a new, innovative antimalarial drug.

In June 2013, Daiichi Sankyo and MMV launched a High-Throughput Screening (HTS) project of a 50,000 compounds library from Daiichi Sankyo with the goal of discovering antimalarial hit compounds. Building on the identification of three hit series during the HTS project, Hit-to-Lead project was launched in March 2015.

As a result of these previous collaborative research projects, two leads that meet the criteria set by the Global Health Innovative Technology Fund (hereafter GHIT Fund) and MMV have been obtained. The collaborative research will now proceed to the next stage as Lead Optimization Project beginning in October 2016. The project goal for the Daiichi Sankyo and MMV project team is to produce a clinical candidate with suitable antimalarial "drug-like" properties.

This collaborative research project is funded through the GHIT Fund's Product Development Platform and will receive approximately 180 million yen over a period of two years.

By developing and producing pharmaceutical agents and improving access to healthcare in developing countries, Daiichi Sankyo is actively contributing towards the third Sustainable Development Goal (SDG) set by the United Nations: ensuring healthy lives and promoting well-being for all people at all ages. Daiichi Sankyo is also contributing to the health and quality of life of people across the globe by participating in this collaborative research project into antimalarial drugs.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X